SAN DIEGO, Dec. 06, 2017 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that its subsidiary, US Compounding, has developed a unique compound to manage ulcers in horses. Ulcers are common in the majority of horses that are subject to stress. Examples of horses under stress include race horses, endurance horses, dressage horses, hunters, jumpers, 3-day eventers and any type of rodeo horse. In general, horses that are in active training tend to have a prevalence of ulcers in the range of 90 to 95%. Historically, ulcers have been known to negatively affect feeding habits and performance on the track.
A study, utilizing US Compounding’s unique drug formulation, was conducted in approximately 50 race horses. Gastric endoscopy was performed at day 0 and any time between days 14 and 21. Drug was administered after the first endoscopy as a paste given orally for 30 days. Endoscopic improvement was seen as early as 14 days. In greater than 95% of the horses the ulcers were shown to be clinically healed, as confirmed by endoscopy, with a reduction in gastric ulcer recovery times. A patent application covering this unique compounded product has been filed by the Company. In addition, a manuscript is in preparation.
Two horses that were receiving US Compounding’s product recently competed in the 2017 Breeders Cup and both placed first in their respective races. Ralph Nicks, trainer for Caledonia Road, stated, “To compete at the elite level your horses must maintain top form. US Compounding products are an integral part of ensuring that our horses do just that”. John Kimmel, trainer for Bar of Gold stated, “US Compounding is an important piece of our team’s continued success. Their products help maintain a level of wellness needed to compete at the top level.”
Dr. Dennis J. Carlo, President and CEO of Adamis stated, “This new compound is the first in the expansion of our veterinary product line. As a side note, since the Breeders Cup, two additional horses using our products won their respective races, one setting a track record.”
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi (epinephrine) Injection 0.3mg, was approved in June 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ product pipeline includes a naloxone injection product candidate using the SymjectTM syringe drug delivery platform, a HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.
The company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.
Adamis Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the outcome of any further studies or trials relating to the USC compound to manage ulcers in horses; the company’s ability to successfully develop additional veterinary products and product candidates; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; and the company’s beliefs concerning the safety and effectiveness of its products and product candidates. There are no assurances concerning the commercial success of the company’s veterinary compound for management of ulcers in horses. In addition, results in any subsequent studies concerning the ulcer compound for horses may be different from the study described in this press release. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from those contemplated by these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Any forward-looking statement in this press release speaks only as of the date on which it is made. Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation